Investors
Company Profile
Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment.
Leveraging decades of expertise in programmable DNA-binding proteins,the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generattion of genetic medicines designed to move beyonf disease management and toward lasting therapeutic impact.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC.
Key press releases
Upcoming events
Covering research analysts
Barclays – Etzer Darout
Citizens Bank – Silvan Tuerkcan
Goldman Sachs – Salveen Richter
Jefferies – Amin Makarem
Kempen – Sebastiaan van der Schoot
Oddo BHF – Martial Descoutures
RW Baird – Jack Allen
Wells Fargo – Yanan Zhu
Cellectis contact information
Arthur Stril, Chief Financial Officer & Chief Business Officer
Citibank ADR contact information
Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030
Société Générale Securities Services – Ordinary Shares contact information
Call center in English and French
Monday to Friday from 8:30am to 6pm CEST
+33 (0)2 51 85 67 89
Get updates
Get the latest on gene-editing innovation, financial and business news from Cellectis with our email alert service.